8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) 
November 14, 2013

ALLIED HEALTHCARE PRODUCTS, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-19266	25-1370721
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1720 Sublette Avenue, St. Louis, Missouri 
(Address of principal executive offices) 63110
(Zip Code)

Registrant’s telephone number, including area code 

(314) 771-2400 

Not applicable 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure.

On November 14, 2013, Allied Healthcare Products, Inc. (the “Company”) is presenting the materials attached to this report as Exhibit 99.1 at its annual stockholder meeting.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Exhibit materials being presented at the Company’s annual stockholder meeting. These materials are being furnished pursuant to Item 7.01 hereof.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ALLIED HEALTHCARE PRODUCTS, INC.
	By:
Date:  November 14, 2013		/s/  Daniel C. Dunn
		Daniel C. Dunn
		Chief Financial Officer

EX-99.1

1 ALLIED HEALTHCARE ANNUAL SHAREHOLDER MEETING November 14, 2013

FY2013 REVIEW ▪ Continued Impact of Recession on Domestic Markets » Hospitals » Municipalities » Government Spending ▪ International Markets » Flat » Major Drop Off Venezuela ▪ Take Off in CO ₂ Absorbent Business 2

US Hospitals Cutting Manning and Purchases ▪ Medicare, Medicaid, private insurance reducing reimbursements to hospitals » Sequestration cut Medicare reimbursements by 2% ▪ New healthcare law further reduced Medicare payments to hospitals with high readmission rates. ▪ NIH Funding for research reduced by 5% - Sequestration. 3

US Hospitals Cutting Manning and Purchases - continued ▪ Inpatient hospital days have fallen 4% from prerecession levels. ▪ Baby Boomers moving into Medicare (age 65) with subsequent Medicare pays lower rates than private insurers. ▪ Federal Government payments for treating uninsured being phased out with Affordable Healthcare Act. 4

▪ Sequestration will pass. ▪ Hospitals will complete their restructuring to accommodate new revenue realities. ▪ Patient days will rise with new population of insured individuals. ▪ Hospitals will return to sustainable equipment purchase levels. 5

FY 2008 to FY 2013 (without non - recurring items) 6 Sales Decline ($16.3) million Profit Impact ($8.1) million Manufacturing/Purchasing Cost Reductions $3.2 million Overhead Cost Reduction $1.4 million New Decline In Pretax Profit ($3.5) million

GOING FORWARD 7 ▪ Continue developing new products to offset recessions’ sales declines. » Mass Casualty Ventilators: Failure in US Moderate Success Internationally » CO ₂ Absorbent Has taken off in FY 2013 Continued excellent growth in FY 2014 » New Full - featured cost effective transport ventilator under review by FDA. ▪ Continue Manufacturing/Purchasing Cost Reductions.

Non - GAAP Financial Measures ▪ The Company has presented its sales decline and decline in pre - tax profit from 2008 to 2013 to exclude non - recurring items described below. The Company believes that these non - GAAP measures are important because they eliminate non - recurring items not expected to occur in the future and allow for comparison of year - over - year performance. These non - GAAP financial measures are not intended to be a substitute for the comparable GAAP measures and should only be read in conjunction with our financial statements prepared in accordance with GAAP. ▪ For this comparison: » During 2008 the Company has not included approximately $1.7 million in sales revenue resulting from the agreement with Abbott Laboratories to cease the production of Baralyme. During 2013, the Company has not included approximately $0.1 million in sales resulting from that same agreement in sales for comparison purposes. This item will not occur in future years after Fiscal 2013. 8

Non - GAAP Financial Measures » For this comparison, during 2008 the Company has not included $0.5 million in pretax profits resulting from the agreement with Abbott Laboratories. During 2013, the Company has not included approximately $0.1 million in pre - tax profit resulting from that same agreement for comparison purposes. This item will not occur in future years after Fiscal 2013. » For this comparison, the Company has not included approximately $0.5 million received resulting from the demutualization of its product liability insurer in pre - tax profit in Fiscal 2013. Any future receipts resulting from this transaction after Fiscal 2013 are not expected to be material. ▪ Without these adjustments reported sales in 2008 were approximately $56.4 million and reported sales in 2013 were approximately $38.6 million. Without these adjustments reported pre - tax income in 2008 was approximately $1.3 million, and reported pre - tax loss in 2013 was a loss of approximately $2.0 million. 9